Business Context and Reporting Period
Company: Curis, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2005
Business Overview: Curis is a therapeutic drug development company focused on modulating regulatory signaling pathways (specifically Hedgehog and BMP) to treat diseases such as cancer, neurological disorders, and hair growth regulation. The company operates primarily through strategic collaborations with major pharmaceutical partners including Genentech, Wyeth, Procter & Gamble, and Johnson & Johnson subsidiaries.
Key Financial Metrics (Year Ended Dec 31, 2005)
| Metric | 2005 (Restated) | 2004 (Restated) |
|---|---|---|
| Gross Revenues | $13,002,000 | $3,699,000 |
| Contra-Revenues (Co-development costs) | ($6,999,000) | $0 |
| Net Revenues | $6,002,000 | $3,699,000 |
| Total Costs & Expenses | $21,870,000 | $20,494,000 |
| Net Loss | ($14,855,000) | ($15,075,000) |
| Cash & Marketable Securities | $44,209,000 | $49,514,000 |
| Working Capital | $36,010,000 | $46,854,000 |
| Accumulated Deficit | ($680,054,000) | ($665,199,000) |
Note: Financial results for 2003 and 2004 have been restated due to accounting errors regarding revenue recognition and expense capitalization.
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 62% to $6.0 million, driven by increased research and development contract revenues ($10.5 million vs. $3.4 million) and license fees ($2.3 million vs. $0.2 million). This growth was partially offset by $7.0 million in contra-revenues related to the co-development of a basal cell carcinoma candidate with Genentech.
- Expense Increases: Research and development expenses rose 8% to $13.7 million, primarily due to increased spending on discovery research programs. General and administrative expenses increased 4% to $8.1 million, including a $500,000 charge for expected loss of subtenant income.
- Restatement Impact: The company restated prior periods to defer $7.5 million in Genentech license fee payments previously recognized as revenue, as the performance obligations were deemed indefinite. Additionally, $410,000 in university license fees were expensed immediately rather than capitalized.
- Liquidity: Cash and cash equivalents decreased by approximately $5.3 million year-over-year, primarily due to operating losses and capital expenditures, though the company maintains a strong cash position relative to its burn rate.
Guidance, Outlook, and Risks
Management Commentary & Outlook
- Clinical Progress: The lead product candidate (topical Hedgehog antagonist for basal cell carcinoma) is in Phase I clinical trials with Genentech. Preliminary data indicated safety and tolerability but less clinical activity than anticipated, leading to a temporary suspension of enrollment in the second segment of the trial. Final results are expected in the first half of 2006.
- Collaborations: New collaborations were established with Genentech (drug discovery) and Procter & Gamble (hair growth). Existing agreements with Wyeth and Genentech were extended.
- Liquidity Runway: Management believes existing capital resources, combined with expected contract payments, are sufficient to fund operations into the second half of 2007. Additional financing may be required thereafter.
Risks and Contingencies
- Financial Restatement: The restatement of financial statements for 2003-2005 creates risk of securities litigation and potential stock price decline.
- Profitability: The company has never been profitable and expects to incur substantial losses for the foreseeable future. It has no current sources of material ongoing revenue from product sales.
- Collaboration Dependency: Revenue is heavily dependent on collaborators (Genentech accounted for 49% of gross revenue in 2005). Termination or delay by partners could severely impact operations.
- Co-Development Costs: The company shares equally in U.S. development costs for the basal cell carcinoma program. Genentech notified Curis in January 2006 of potential invoicing errors, estimating an additional liability of $325,000 to $667,000.
Investor Verification Checklist
- Restatement Details: Verify the specific impact of the revenue recognition restatement on deferred revenue balances and future earnings potential.
- Phase I Trial Results: Monitor the final results of the basal cell carcinoma Phase I trial expected in H1 2006 to determine if the program advances to Phase II.
- Co-Development Liability: Confirm the final amount owed to Genentech regarding the invoicing errors and its impact on cash flow.
- Cash Burn Rate: Assess the sufficiency of the $44.2 million cash balance to sustain operations through mid-2007 given the high R&D spend and lack of product revenue.
- Sublease Risk: Evaluate the risk associated with the potential vacancy of the 61 Moulton Street facility and the $500,000 charge already recorded for lost subtenant income.